Combination therapy before surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of liver cancer (hepatocellular carcinoma).
- Your cancer should be at an intermediate or advanced stage, but confined to the liver (no spread to other organs).
- You must not have received any prior cancer drugs for liver cancer (like systemic therapy).
- You must be in good general health (ECOG 0 or 1) and have adequate liver and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—chemo given directly into the liver, an oral targeted therapy, and an immunotherapy—for people with liver cancer that could be removed by surgery but isn't the first choice right now. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
This trial combines an immunotherapy (Envafolimab), a targeted therapy (Suvemcitug), and a special chemotherapy infusion that goes directly into the liver (HAIC) to try to shrink or control advanced liver cancer that can't be removed by surgery. The goal is to help convert the tumor to a state where it might be operable, and to improve long-term outcomes.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
This trial tests whether giving a combination of targeted therapy and immunotherapy before surgery can shrink liver tumors and improve outcomes in people with intermediate-stage liver cancer. The study uses a special computer model to see if you might benefit from this approach.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
Hear when a new Potentially Resectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.